Navigation Links
Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
Date:5/5/2009

ical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Evoke Pharma that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Evoke Pharma's business including, without limitation, statements about: difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products; unexpected performance of side effects of its products that could delay or prevent development or commercialization; the scope and validity of patent protection for its products; competition form other pharmaceutical companies; and its ability to obtain additional financing to support is operations. All forward-looking statements are qualified in their entirety by this cautionary statement and Evoke Pharma undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE Evoke Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
2. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
3. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
4. China Biopharma, Inc. Announces New Plan of Operation
5. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
6. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
7. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
8. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
9. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
10. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
11. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader ... company overview at the Nomura Biotechnology Conference on Thursday, November ... MA. A live webcast of the ... of the Company,s website, www.isispharm.com .  A replay will ... will be archived for a limited time. About ...
(Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
(Date:10/27/2014)... and TORONTO , Oct. 27, ... ) (OTCQB: GNBT) today announced two presentations demonstrating ... by its novel proprietary cancer immunotherapeutic AE37 vaccine ... cancer patients. The AE37 cancer vaccine is being ... Inc. ( www.antigenexpress.com ). The presentations are being ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... and GERMANTOWN, Maryland, May 3, 2012 ... assay to detect rupture of fetal membranes (ROM)   - ... Novel FDA-cleared test is highly synergistic with ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today announced ...
... ANGELES, May 3, 2012 MD+DI ( ... brand providing the medical device industry with the latest news ... for Best Cover in the Medical, Dental & Related ... May 2011 cover was also a finalist for the ...
... Corporation (Nasdaq: VRNM ), a leading industrial biotechnology ... today announced that it will release 2012 first ... close. In conjunction with the release, the Company will host ... at 5:00 p.m. ET. The call may be ...
Cached Biology Technology:QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 2QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 3QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 4QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 5MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category 2Verenium Corporation To Announce First Quarter 2012 Financial Results 2
(Date:10/29/2014)... Researching the safety of nanoparticles is all the rage. ... topic, examining the question of whether titanium dioxide nanoparticles ... into the body, whether carbon nanotubes from electronic products ... to be or whether nanoparticles in food can get ... Public interest is great, research funds are flowing – ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... new study on a large cohort of kidney cancer ... of the disease -- and reveals an apparent link ... cancer, particularly in Romania. , The research, by an ... and Genome Quebec Innovation Centre in Montreal, underscores the ... acid. The compound, found in plants of the Aristolochia ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3
... Virology group at the Institute for Molecular Medicine Finland ... national and international collaborators, developed a new cell screening ... drugs. The researchers were able to identify two novel ... the efficacy of a previously known drug saliphenylhalamide. ...
... to discontinue in 2013 a unique environmental research project that ... topics for almost 40 years would be a "huge loss ... humanity." That,s the focus of a viewpoint article in ACS, ... Hering, D. L. Swackhamer and W. H. Schlesinger explain that ...
... on the Florida campus of The Scripps Research Institute have ... for one of the diseases closely linked to fragile X ... memory impairment, and is the only known single-gene cause of ... the journal ACS Chemical Biology September 4, 2012, ...
Cached Biology News:Harnessing anticancer drugs for the future fight against influenza 2Scripps Florida scientists design molecule that reverses some fragile X syndrome defects 2
... Forma's stainless steel rack ... adjustable mechanism that permits ... shaking angles, and "snap-in" ... universal rack holder will ...
... Source: Escherichia coli RY 13 5'G AATTC3' 3'CTTAA ... 15 min or ethanol precipitation. Storage Conditions: 10mM ... DTT, 0.15% Triton X-100, 0.01% BSA, 50% glycerol. ... at -20C. Unit Definition: One unit is defined ...
... shaker flask clips, purpose-designed to firmly retain ... clips are equipped with a top retainer ... a bottom retainer spring, and silicon tubing ... glassware. Clips include the required mounting ...
ANTI DIPHTH TOX A SU...
Biology Products: